Edison and Dainippon Sumitomo Broaden Relationship with Discovery Alliance Targeting Redox Biochemistry
By Heather Cartwright
Pharma Deals Review: Vol 2014 Issue 2 (Table of Contents)
Published: 22 Feb-2014
DOI: 10.3833/pdr.v2014.i2.2011 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
Redox drug developer Edison Pharmaceuticals has secured a significant expansion of its existing licensing agreement with Japan’s Dainippon Sumitomo Pharma (DSP) that could be worth as much as US$4...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS